533 related articles for article (PubMed ID: 30098165)
21. Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
Sekine L; Ziegelmann PK; Manica D; da Fonte Pithan C; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
Hematol Oncol; 2019 Feb; 37(1):62-74. PubMed ID: 30129104
[TBL] [Abstract][Full Text] [Related]
22. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.
Al-Ani F; Louzada M
Eur J Haematol; 2017 Dec; 99(6):479-488. PubMed ID: 28885719
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials.
Wang L; Xu YL; Zhang XQ
Leuk Lymphoma; 2014 Jul; 55(7):1479-88. PubMed ID: 23998282
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis.
Giri S; Aryal MR; Yu H; Grimshaw A; Pathak R; Huntington SP; Dhakal B
J Geriatr Oncol; 2020 Nov; 11(8):1285-1292. PubMed ID: 32513568
[TBL] [Abstract][Full Text] [Related]
25. A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma.
Mohyuddin GR; Hampton J; Aziz M; Khuder S; Malik S; McClune B; Abdallah AO
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):489-496. PubMed ID: 33962898
[TBL] [Abstract][Full Text] [Related]
26. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
[TBL] [Abstract][Full Text] [Related]
27. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
29. First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.
Kuhr K; Wirth D; Srivastava K; Lehmacher W; Hellmich M
Eur J Clin Pharmacol; 2016 Mar; 72(3):257-65. PubMed ID: 26671239
[TBL] [Abstract][Full Text] [Related]
30. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
31. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group.
Luoma S; Anttila P; Säily M; Lundan T; Heiskanen J; Siitonen T; Kakko S; Putkonen M; Ollikainen H; Terävä V; Sankelo M; Partanen A; Launonen K; Räsänen A; Sikiö A; Suominen M; Bazia P; Kananen K; Lievonen J; Selander T; Pelliniemi TT; Ilveskero S; Huotari V; Mäntymaa P; Tienhaara A; Jantunen E; Silvennoinen R
Ann Hematol; 2019 Dec; 98(12):2781-2792. PubMed ID: 31673775
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
Zou Y; Lin M; Sheng Z; Niu S
Leuk Lymphoma; 2014 Sep; 55(9):2024-31. PubMed ID: 24067138
[TBL] [Abstract][Full Text] [Related]
34. Risk adapted post-transplant maintenance in multiple myeloma.
Vaxman I; Gertz M
Expert Rev Hematol; 2019 Feb; 12(2):107-118. PubMed ID: 30696304
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
36. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
[No Abstract] [Full Text] [Related]
37. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
Kumar A; Hozo I; Wheatley K; Djulbegovic B
Am J Hematol; 2011 Jan; 86(1):18-24. PubMed ID: 21120867
[TBL] [Abstract][Full Text] [Related]
38. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J
Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306
[TBL] [Abstract][Full Text] [Related]
40. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.
Weisel K; Doyen C; Dimopoulos M; Yee A; Lahuerta JJ; Martin A; Travers K; Druyts E; Toor K; Abildgaard N; Lu J; Van Droogenbroeck J; Geraldes C; Petrini M; Voillat L; Voog E; Facon T
Leuk Lymphoma; 2017 Jan; 58(1):153-161. PubMed ID: 27124703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]